AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 NOV 12 - (NewsRx.com & NewsRx.net) -- Data from five large studies with an investigational intranasal, cold-adapted trivalent influenza vaccine (CAIV-T) were presented at the Fifth International Options for the Control of Influenza Conference in Okinawa, Japan.
The studies involved nearly 5500 individuals from a wide range of populations, including infants as young as 6 weeks of age, young children in day care settings, adults aged 60 years or older, and healthy adult males from 24 to 45 years of age.
"These data are very encouraging and will be important additions to our ongoing development plans for our next generation intranasal flu vaccine program," said Peter Paradiso, VP, new business, and scientific affairs for Wyeth.
James F. Young, PhD, MedImmune's president, research and development, said, "The cold-adapted flu technology used to manufacture CAIV-T - a liquid, refrigerator-stable formulation - is the same technology used to make the current frozen version of FluMist (Influenza Virus Vaccine Live, Intranasal), which is the first needle-free flu vaccine approved in the United States.
FluMist is currently indicated for healthy people 5-49 years of age. The data presented at the Options conference ...
Source: HighBeam Research, Phase III data for influenza vaccine presented at conference.